2019
Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2–Directed Chemotherapy in HER2-Positive Breast Cancer
Meisel J, Zhao J, Suo A, Zhang C, Wei Z, Taylor C, Aneja R, Krishnamurti U, Li Z, Nahta R, O'Regan R, Li X. Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2–Directed Chemotherapy in HER2-Positive Breast Cancer. Clinical Breast Cancer 2019, 20: 19-24. PMID: 31806448, DOI: 10.1016/j.clbc.2019.09.003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreastBreast NeoplasmsCarcinoma, Ductal, BreastChemotherapy, AdjuvantDNA Copy Number VariationsDrug Resistance, NeoplasmFeasibility StudiesFemaleHumansLymphocytes, Tumor-InfiltratingMastectomyMiddle AgedNeoadjuvant TherapyPredictive Value of TestsProgression-Free SurvivalReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTumor BurdenConceptsTumor-infiltrating lymphocytesHER2-positive breast cancerNeoadjuvant therapyHER2/CEP17 ratioBreast cancerClinicopathologic featuresTumor sizeEstrogen receptorKi-67High HER2/CEP17 ratioCEP17 ratioHER2 immunohistochemistry 3Pathologic complete responseProgesterone receptor expressionSmaller tumor sizeBreast cancer responseHigh Ki-67Low estrogen receptorHER2 copy numberRCB-IIPatient ageClinicopathologic factorsComplete responseInitial biopsyExcisional specimens
2017
New Developments in Breast Cancer and Their Impact on Daily Practice in Pathology
Li X, Oprea-Ilies G, Krishnamurti U. New Developments in Breast Cancer and Their Impact on Daily Practice in Pathology. Archives Of Pathology & Laboratory Medicine 2017, 141: 490-498. PMID: 28353377, DOI: 10.5858/arpa.2016-0288-sa.Peer-Reviewed Original ResearchConceptsBreast cancerDaily practiceBreast specimensTriple-negative breast cancerDistinct biological subsetsHER2/neu gene amplificationTumor-infiltrating lymphocytesRadioactive seed localizationAppropriate treatment groupsNovel clinical practicesNeu gene amplificationNeoadjuvant treatmentPathologic evaluationHistopathologic parametersTreatment groupsClinical practiceTherapeutic utilityBiological subsetsCancerMolecular classificationBest treatmentPathologyNew guidelinesSeed localizationGene amplificationTumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor–positive breast cancers
Krishnamurti U, Wetherilt C, Yang J, Peng L, Li X. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor–positive breast cancers. Human Pathology 2017, 64: 7-12. PMID: 28153508, DOI: 10.1016/j.humpath.2017.01.004.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBiopsyBreast NeoplasmsChemotherapy, AdjuvantDisease ProgressionDisease-Free SurvivalFemaleHumansLogistic ModelsLymphatic MetastasisLymphocytes, Tumor-InfiltratingMastectomyMultivariate AnalysisNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioPredictive Value of TestsProportional Hazards ModelsReceptors, EstrogenRisk FactorsTime FactorsTreatment OutcomeTriple Negative Breast NeoplasmsConceptsTriple-negative breast cancerTumor-infiltrating lymphocytesDisease-free survivalBetter overall survivalLymph node statusOverall survivalBreast cancerNeoadjuvant treatmentLymphovascular invasionEstrogen receptor-positive breast cancerReceptor-positive breast cancerOncotype DX recurrence scoreOncotype DX scorePossible prognostic valueDX recurrence scoreNottingham histologic gradeNeoadjuvant settingTILs correlateNegative associationNode statusPrognostic valueRecurrence scoreHistologic gradePrognostic parametersPathological response
2016
Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer
Li X, Wetherilt C, Krishnamurti U, Yang J, Ma Y, Styblo T, Meisel J, Peng L, Siddiqui M, Cohen C, Aneja R. Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer. American Journal Of Clinical Pathology 2016, 146: 496-502. PMID: 27686176, DOI: 10.1093/ajcp/aqw134.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerBetter disease-free survivalDisease-free survivalPD-L1 expressionPD-L1 stainingTumor-infiltrating lymphocytesStromal PD-L1 expressionPD-1 stainingLymphovascular invasionOverall survivalBreast cancerH-scoreTNBC casesTumor sizeCell death protein 1PD-1 expressionLymph node statusDeath protein 1Worse overall survivalKi-67 scoreFull-face sectionsNottingham histologic gradeNeoadjuvant therapyPD-1Node status